291 related articles for article (PubMed ID: 36768484)
21. Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.
Ballatore C; Brunden KR; Huryn DM; Trojanowski JQ; Lee VM; Smith AB
J Med Chem; 2012 Nov; 55(21):8979-96. PubMed ID: 23020671
[TBL] [Abstract][Full Text] [Related]
22. Development of tau aggregation inhibitors for Alzheimer's disease.
Bulic B; Pickhardt M; Schmidt B; Mandelkow EM; Waldmann H; Mandelkow E
Angew Chem Int Ed Engl; 2009; 48(10):1740-52. PubMed ID: 19189357
[TBL] [Abstract][Full Text] [Related]
23. Measurement of Tau Filament Fragmentation Provides Insights into Prion-like Spreading.
Kundel F; Hong L; Falcon B; McEwan WA; Michaels TCT; Meisl G; Esteras N; Abramov AY; Knowles TJP; Goedert M; Klenerman D
ACS Chem Neurosci; 2018 Jun; 9(6):1276-1282. PubMed ID: 29590529
[TBL] [Abstract][Full Text] [Related]
24. Tauopathies.
Hernández F; Avila J
Cell Mol Life Sci; 2007 Sep; 64(17):2219-33. PubMed ID: 17604998
[TBL] [Abstract][Full Text] [Related]
25. Tau Proteins and Tauopathies in Alzheimer's Disease.
Chong FP; Ng KY; Koh RY; Chye SM
Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
[TBL] [Abstract][Full Text] [Related]
26. Trans-seeding of Alzheimer-related tau protein by a yeast prion.
Flach M; Leu C; Martinisi A; Skachokova Z; Frank S; Tolnay M; Stahlberg H; Winkler DT
Alzheimers Dement; 2022 Dec; 18(12):2481-2492. PubMed ID: 35142027
[TBL] [Abstract][Full Text] [Related]
27. Assays for the Screening and Characterization of Tau Aggregation Inhibitors.
Horsley D; Rickard JE; Vorley T; Leeper MF; Wischik CM; Harrington CR
Methods Mol Biol; 2024; 2754():93-104. PubMed ID: 38512662
[TBL] [Abstract][Full Text] [Related]
28. Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies.
Pickhardt M; Neumann T; Schwizer D; Callaway K; Vendruscolo M; Schenk D; St George-Hyslop P; Mandelkow EM; Dobson CM; McConlogue L; Mandelkow E; Tóth G
Curr Alzheimer Res; 2015; 12(9):814-28. PubMed ID: 26510979
[TBL] [Abstract][Full Text] [Related]
29. Targeting tau: Clinical trials and novel therapeutic approaches.
VandeVrede L; Boxer AL; Polydoro M
Neurosci Lett; 2020 Jul; 731():134919. PubMed ID: 32380145
[TBL] [Abstract][Full Text] [Related]
30. Propagation of Tau Aggregates and Neurodegeneration.
Goedert M; Eisenberg DS; Crowther RA
Annu Rev Neurosci; 2017 Jul; 40():189-210. PubMed ID: 28772101
[TBL] [Abstract][Full Text] [Related]
31. Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.
Ballatore C; Brunden KR; Trojanowski JQ; Lee VM; Smith AB; Huryn DM
Curr Top Med Chem; 2011; 11(3):317-30. PubMed ID: 21320060
[TBL] [Abstract][Full Text] [Related]
32. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody.
Albert M; Mairet-Coello G; Danis C; Lieger S; Caillierez R; Carrier S; Skrobala E; Landrieu I; Michel A; Schmitt M; Citron M; Downey P; Courade JP; Buée L; Colin M
Brain; 2019 Jun; 142(6):1736-1750. PubMed ID: 31038156
[TBL] [Abstract][Full Text] [Related]
33. Espresso Coffee Mitigates the Aggregation and Condensation of Alzheimer's Associated Tau Protein.
Tira R; Viola G; Barracchia CG; Parolini F; Munari F; Capaldi S; Assfalg M; D'Onofrio M
J Agric Food Chem; 2023 Aug; 71(30):11429-11441. PubMed ID: 37466260
[TBL] [Abstract][Full Text] [Related]
34. Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.
Strang KH; Croft CL; Sorrentino ZA; Chakrabarty P; Golde TE; Giasson BI
J Biol Chem; 2018 Feb; 293(7):2408-2421. PubMed ID: 29259137
[TBL] [Abstract][Full Text] [Related]
35. Chaperoning shape-shifting tau in disease.
Ryder BD; Wydorski PM; Hou Z; Joachimiak LA
Trends Biochem Sci; 2022 Apr; 47(4):301-313. PubMed ID: 35045944
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of tau self-aggregation and neurotoxicity.
Farías G; Cornejo A; Jiménez J; Guzmán L; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):608-14. PubMed ID: 21605046
[TBL] [Abstract][Full Text] [Related]
37. The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies.
Lozupone M; Dibello V; Sardone R; Castellana F; Zupo R; Lampignano L; Bortone I; Stallone R; Altamura M; Bellomo A; Daniele A; Solfrizzi V; Panza F
Expert Opin Drug Discov; 2023 May; 18(5):515-526. PubMed ID: 37042028
[TBL] [Abstract][Full Text] [Related]
38. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
Stancu IC; Ferraiolo M; Terwel D; Dewachter I
Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
[TBL] [Abstract][Full Text] [Related]
39. Characterization of Posttranslationally Modified PHF-1 Tau Peptides Using Gaussian Accelerated Molecular Dynamics Simulation.
Barbhuiya TK; Jayarathna DK; Gilmour R; Smet-Nocca C; Gandhi NS
Methods Mol Biol; 2024; 2754():3-31. PubMed ID: 38512658
[TBL] [Abstract][Full Text] [Related]
40. Continuous Monitoring of Tau-Induced Neurotoxicity in Patient-Derived iPSC-Neurons.
Oakley DH; Klickstein N; Commins C; Chung M; Dujardin S; Bennett RE; Hyman BT; Frosch MP
J Neurosci; 2021 May; 41(19):4335-4348. PubMed ID: 33893219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
